Analyst Reiterates Buy on Prothena, Maintaining $30 Price Target on CYTOPE and PRX012-TfR Platform Strength
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Andrew Fein has reiterated a Buy rating on Prothena (PRTA) with a $30 price target, citing the strength of its CYTOPE and PRX012-TfR platforms. He highlights CYTOPE's preclinical evidence in ALS models and its modular design, which can be adapted for various applications. Fein also notes the competitive positioning of PRX012-TfR in Alzheimer's treatment. Citizens JMP has similarly maintained a Buy rating with a $20 price target. Fein is recognized as a 5-star analyst with a strong track record in the Healthcare sector.
H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on PRTA stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Andrew Fein has given his Buy rating due to a combination of factors centered on Prothena’s advancing CYTOPE and PRX012-TfR platforms, which he views as the core value drivers in the company’s wholly owned pipeline. He highlights CYTOPE’s compelling preclinical evidence in pTDP-43, noting that it meaningfully reduces toxic aggregates and corrects abnormal RNA splicing in ALS models, while safely accessing the cytosol through a non-disruptive endosomal escape mechanism.
Fein also emphasizes the modular design of CYTOPE, which can be adapted to antibodies, ASOs, and siRNAs, broadening its potential to other intracellular proteinopathies like α-synuclein and tau. On PRX012-TfR, he sees the transferrin receptor–based brain shuttle as a way to deepen amyloid-β clearance while limiting ARIA risk, positioning the program competitively in the Alzheimer’s landscape; accordingly, he reiterates a Buy rating and maintains his $30 price target.
According to TipRanks, Fein is a 5-star analyst with an average return of 27.0% and a 57.03% success rate. Fein covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Palvella Therapeutics, and Denali Therapeutics.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $20.00 price target.